Deutsche Bank Boosts Price Target on Genentech (DNA) to $85
More News related to DNA
- A Company and Industry Analysis of North America's Biotechnology Sectors: Understand the Regulatory Environment, Current Breakthroughs & the Market Outlook
- Register Your Company Now for the 2009 IR Global Rankings
- Genentech (DNA) and Biogen (BIIB) Announce Phase III Study of Rituxan(R) Met Primary Endpoint
- Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
- Morning Movers 10/06: Citigroup (C) Lower on Wachovia Battle; Imclone (IMCL) Up After Eli Lilly Takeover
More News related to Analyst Comments
- AmTech Reiterates Sell on Amazon (AMZN); Cuts PT to $45
- Canaccord Adams Maintains 'Buy' Rating on VALE (RIO), but Lowers Price Target
- Canaccord Adams Maintains 'Buy' Rating on Thompson Creek Metals (TC)
- Canaccord Adams Maintains 'Buy' Rating on Taseko Mines Limited (TGB)
- Analyst Starts Coverage on Solar Sector with an Underperform; Sees Stocks Falling At Least Another 30-40%
Deutsche Bank raised its price target on Genentech (NYSE: DNA) from $83 to $85, maintaining their Buy rating, following Q2 results. The firm noted that while EPS was light, Avastin sales are finally growing again.
The firm said, "Avastin US sales of $650M best consensus by ~$5M and importantly grew sequentially for the first time since 3Q07. We think the number was real & sustainable, driven by increased uptake in breast cancer."
Related Categories
Analyst CommentsStocks Mentioned
-5.75Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
